Analytical Data
-
Gene name
E7
- Application
-
Alternative Names
E7; Protein E7
-
Species
Human papillomavirus type 16
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P03129
-
Expression Region
1-98aa
-
Molecular Weight
13.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The E7 protein, an oncoprotein derived from the human papillomavirus (HPV), has garnered significant attention in cancer research due to its pivotal role in the development of cervical cancer and other HPV-related malignancies. HPV infects epithelial cells, and the E7 protein disrupts normal cell cycle regulation by interfering with host cell tumor suppressor pathways, particularly those involving the retinoblastoma (Rb) protein. This disruption promotes uncontrolled cellular proliferation, contributing to malignant transformation. Research surrounding E7 has focused on its molecular interactions, mechanisms of action, and potential as a target for therapeutic interventions. Studies have demonstrated that E7 can evade the immune response, making it a candidate for vaccination strategies aimed at eliciting robust anti-tumor immune responses. Additionally, E7 is used as a biomarker for HPV-related cancers, enhancing early detection and diagnostic measures. With the growing incidence of HPV-associated cancers worldwide, understanding the biology of the E7 protein is essential for developing targeted therapies, improving vaccine effectiveness, and ultimately reducing the burden of these diseases. Ongoing research includes the development of E7-based immunotherapies and novel approaches to inhibit its oncogenic functions, with the aim of translating these findings into clinical applications that could benefit patients diagnosed with HPV-related cancers.
